Skip to main content
UnicoCell logo

UnicoCell — Investor Relations & Filings

Ticker · 6794 ISIN · TW0006794001 TW Professional, scientific and technical activities
Open in API
Filings indexed 37 across all filing types
Latest filing 2026-06-03 Governance Information
Country TW Taiwan
Listing TW 6794

About UnicoCell

https://www.unicocell.com

UnicoCell Biomed Co., Ltd. specializes in regenerative medicine, focusing on the research, development, and clinical application of stem cell technologies. The company’s operations are centered on three primary axes: the development of novel stem cell therapeutics, the production of stem cell-derived exosomes, and the provision of cell manufacturing and Contract Development and Manufacturing Organization (CDMO) services. Its lead candidate, ELIXCYTE, is an adipose-derived stem cell therapy undergoing Phase 3 clinical trials for indications such as knee osteoarthritis and chronic kidney disease. Additionally, the company maintains an allogeneic stem cell bank and provides autologous adipose-derived stem cell therapy services. Utilizing patented manufacturing processes and proprietary technology, UnicoCell offers integrated solutions from research to large-scale production to address unmet medical needs in the regenerative therapy sector.

Recent filings

Filing Released Lang Actions
115年年報及股東會資料 — 2026_6794_20260520F14.pdf
Governance Information Classification · 92% confidence The document contains detailed internal procedures for acquiring and disposing corporate assets, outlining board and management approval thresholds, controls, roles, and regulatory compliance steps. It is not a financial report, earnings release, or announcement, but rather a governance manual defining the company’s internal rules and processes. This aligns with the Governance Information category.
2026-06-03 Chinese
115年年報及股東會資料 — 2026_6794_20260520F05.pdf
AGM Information Classification · 95% confidence The document is a detailed record (“議事錄”) of the company’s Annual General Meeting (股東常會), including agenda items, reports, resolutions, voting results, and attachments. It is not the annual report itself, nor a simple voting result announcement, but the full minutes of the AGM. This falls squarely under AGM Information (AGM-R).
2026-06-03 Chinese
本公司脂肪幹細胞新藥ELIXCYTE治療膝骨關節炎 (Knee Osteoarthritis)之人體臨床試驗，向衛生福利部 提出申請臨床試驗設計變更。
Regulatory Filings Classification · 85% confidence The document is a Taiwanese public information disclosure of a material event (clinical trial design change) filed under the stock exchange’s regulations (“重大訊息” clause 10), with no actual financial statements or formal report attached. It is neither an annual or interim financial report nor any of the specified categories like dividends, M&A, or director dealings. It is thus a general regulatory announcement, so it falls under Regulatory Filings (RNS).
2026-05-29 Chinese
功能性委員會成員
Governance Information Classification · 75% confidence The document is a public disclosure from the “公開資訊觀測站” listing the composition of a company committee (convener, members, required expertise, operations). This is not minutes of a shareholder vote or a meeting announcement, nor is it financial statements or an earnings release. It fits “Governance Information” as it details board/committee structure and governance practices (Code: CGR).
2026-05-21 Chinese
功能性委員會成員
Governance Information Classification · 80% confidence The document is a table from the public information observatory listing a company’s board composition: convener, members, independent directors count, total directors count, and financial expertise. There is no indication of a change event (no appointment or resignation) and it focuses on governance structure. This matches a Governance Information report (CGR).
2026-05-21 Chinese
公告本公司董事會委任薪資報酬委員會委員
Board/Management Information Classification · 85% confidence The document is a corporate disclosure on the public information observatory (公開資訊觀測站) announcing changes in the board-level remuneration committee membership. It lists former and new independent directors, effective dates, and reasons. This is an announcement of changes in the company’s board/management structure, matching the Board/Management Information category (MANG).
2026-05-20 Chinese

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.